158 related articles for article (PubMed ID: 36031886)
21. Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis.
Wang H; Zhang S; Yee D; Basu S; Beckwith H; Potter D; Blaes A
Breast Cancer; 2021 May; 28(3):618-629. PubMed ID: 33387284
[TBL] [Abstract][Full Text] [Related]
22. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.
Martel S; Poletto E; Ferreira AR; Lambertini M; Sottotetti F; Bertolini I; Montemurro F; Bernardo A; Risi E; Zanardi E; Ziliani S; Mura S; Dellepiane C; Del Mastro L; Minisini AM; Puglisi F
Breast; 2018 Feb; 37():142-147. PubMed ID: 29161652
[TBL] [Abstract][Full Text] [Related]
23. Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy.
Takada K; Kashiwagi S; Asano Y; Goto W; Ishihara S; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M
BMC Cancer; 2021 Oct; 21(1):1129. PubMed ID: 34670511
[TBL] [Abstract][Full Text] [Related]
24. Effect of Obesity on Neoadjuvant Systemic Therapy Outcomes in Patients with Early Breast Cancer: A Retrospective Institutional Study.
Rasmy A; Sorour Y
Asian Pac J Cancer Prev; 2020 Mar; 21(3):683-691. PubMed ID: 32212794
[TBL] [Abstract][Full Text] [Related]
25. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
[TBL] [Abstract][Full Text] [Related]
26. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.
Broglio KR; Quintana M; Foster M; Olinger M; McGlothlin A; Berry SM; Boileau JF; Brezden-Masley C; Chia S; Dent S; Gelmon K; Paterson A; Rayson D; Berry DA
JAMA Oncol; 2016 Jun; 2(6):751-60. PubMed ID: 26914222
[TBL] [Abstract][Full Text] [Related]
27. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
28. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer.
Litton JK; Gonzalez-Angulo AM; Warneke CL; Buzdar AU; Kau SW; Bondy M; Mahabir S; Hortobagyi GN; Brewster AM
J Clin Oncol; 2008 Sep; 26(25):4072-7. PubMed ID: 18757321
[TBL] [Abstract][Full Text] [Related]
29. Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival.
Orsaria P; Grasso A; Ippolito E; Pantano F; Sammarra M; Altomare C; Cagli B; Costa F; Perrone G; Soponaru G; Caggiati L; Vanni G; Buonomo OC; Altomare V
Anticancer Res; 2021 May; 41(5):2697-2709. PubMed ID: 33952501
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
31. Impact of body mass index and its change on survival outcomes in patients with early breast cancer: A pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials.
Chen H; Qian X; Tao Y; Wang D; Wang Y; Yu Y; Yao H
Breast; 2023 Oct; 71():1-12. PubMed ID: 37429049
[TBL] [Abstract][Full Text] [Related]
32. Obesity or overweight is associated with worse pathological response to neoadjuvant chemotherapy among Chinese women with breast cancer.
Chen S; Chen CM; Zhou Y; Zhou RJ; Yu KD; Shao ZM
PLoS One; 2012; 7(7):e41380. PubMed ID: 22848477
[TBL] [Abstract][Full Text] [Related]
33. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
34. The association between body mass index and immunohistochemical subtypes in breast cancer.
Sahin S; Erdem GU; Karatas F; Aytekin A; Sever AR; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():227-236. PubMed ID: 27756509
[TBL] [Abstract][Full Text] [Related]
35. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
[TBL] [Abstract][Full Text] [Related]
36. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
37. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
38. Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy.
Zarotti C; Papassotiropoulos B; Elfgen C; Dedes K; Vorburger D; Pestalozzi B; Trojan A; Varga Z
Sci Rep; 2022 Jan; 12(1):91. PubMed ID: 34997055
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
Kogawa T; Fujii T; Wu J; Harano K; Fouad TM; Liu DD; Shen Y; Masuda H; Krishnamurthy S; Chavez-MacGregor M; Lim B; Murthy RK; Valero V; Tripathy D; Ueno NT
Oncologist; 2020 Jun; 25(6):e909-e919. PubMed ID: 32003919
[TBL] [Abstract][Full Text] [Related]
40. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy.
Asaoka M; Narui K; Suganuma N; Chishima T; Yamada A; Sugae S; Kawai S; Uenaka N; Teraoka S; Miyahara K; Kawate T; Sato E; Nagao T; Matsubara Y; Gandhi S; Takabe K; Ishikawa T
Eur J Surg Oncol; 2019 Dec; 45(12):2289-2294. PubMed ID: 31787153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
